TY - JOUR
T1 - Pharmacogenetics
T2 - Implications for therapy in rheumatic diseases
AU - Davila, Lesley
AU - Ranganathan, Prabha
N1 - Funding Information:
The ultimate goal of pharmacogenetics in rheumatology is to define genetically distinct subsets of patients who have differential responses to the various therapies used to treat rheumatic diseases. The ideal pharmacogenetic assay would quickly, accurately and inexpensively provide composite genotypes for an individual patient, to enable selection of the most suitable drug for that patient. Although it should be acknowledged that such an assay is currently unavailable, the commitment of major funding agencies to pharmacogenetic research is evident through the establishment of the International HapMap Consortium113and the Pharmacogenetics Research Network114 by the National Institutes of Health. Continued research in this burgeoning field is sure to fulfill the promise of individualized drug therapy in the rheumatic diseases in the near future.
PY - 2011/9
Y1 - 2011/9
N2 - DMARDs not only improve the joint pain and swelling associated with rheumatoid arthritis (RA), but also slow down the joint damage associated with the disease. The efficacy of biologic therapies, introduced in the past decade for the treatment of RA, has been unequivocally established. Similarly, in addition to traditional drugs such as hydroxychloroquine, new biologic agents such as rituximab have been introduced for systemic lupus erythematosus in recent years. However, considerable variability occurs in the responses of patients to these therapies. Pharmacogenetics, the study of variations in genes encoding drug transporters, drug-metabolizing enzymes and drug targets, and their translation to differential responses to drugs, is a rapidly progressing field in rheumatology. Pharmacogenetic applications, particularly to the old vanguard DMARD, methotrexate, and the newer, more expensive biologic agents, might make personalized therapy in rheumatic diseases possible. The pharmacogenetics of commonly used DMARDs and of biologic therapies are described in this Review.
AB - DMARDs not only improve the joint pain and swelling associated with rheumatoid arthritis (RA), but also slow down the joint damage associated with the disease. The efficacy of biologic therapies, introduced in the past decade for the treatment of RA, has been unequivocally established. Similarly, in addition to traditional drugs such as hydroxychloroquine, new biologic agents such as rituximab have been introduced for systemic lupus erythematosus in recent years. However, considerable variability occurs in the responses of patients to these therapies. Pharmacogenetics, the study of variations in genes encoding drug transporters, drug-metabolizing enzymes and drug targets, and their translation to differential responses to drugs, is a rapidly progressing field in rheumatology. Pharmacogenetic applications, particularly to the old vanguard DMARD, methotrexate, and the newer, more expensive biologic agents, might make personalized therapy in rheumatic diseases possible. The pharmacogenetics of commonly used DMARDs and of biologic therapies are described in this Review.
UR - http://www.scopus.com/inward/record.url?scp=80052393117&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80052393117&partnerID=8YFLogxK
U2 - 10.1038/nrrheum.2011.117
DO - 10.1038/nrrheum.2011.117
M3 - Review article
C2 - 21826093
AN - SCOPUS:80052393117
SN - 1759-4790
VL - 7
SP - 537
EP - 550
JO - Nature Reviews Rheumatology
JF - Nature Reviews Rheumatology
IS - 9
ER -